S
2.82
-0.04 (-1.40%)
| Previous Close | 2.86 |
| Open | 2.92 |
| Volume | 4,590,394 |
| Avg. Volume (3M) | 1,023,811 |
| Market Cap | 490,829,440 |
| Price / Book | 3.29 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Diluted EPS (TTM) | -0.480 |
| Total Debt/Equity (MRQ) | 15.66% |
| Current Ratio (MRQ) | 13.73 |
| Operating Cash Flow (TTM) | -89.09 M |
| Levered Free Cash Flow (TTM) | -51.50 M |
| Return on Assets (TTM) | -32.78% |
| Return on Equity (TTM) | -61.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Savara, Inc. | Bearish | Bearish |
AIStockmoo Score
1.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Average | 1.38 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 5.23% |
| % Held by Institutions | 97.25% |
| 52 Weeks Range | ||
| Median | 6.00 (112.77%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 28 Mar 2025 | 6.00 (112.77%) | Buy | 2.91 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |